Indication
For induction of remission and consolidation in adult patients with: • Newly diagnosed, low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤10 x 103/µl) in combination with all-trans-retinoic acid (ATRA) • Relapsed/refractory APL (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.

Medicine details

Medicine name:
arsenic trioxide (Trisenox)
SMC ID:
SMC2181
Pharmaceutical company
Teva UK Limited
BNF chapter
Submission type
Resubmission
Status
Publication due date:
08 July 2019
SMC meeting date:
04 June 2019
Patient group submission deadline:
01 April 2019